Monthly Archives: March, 2017
ACTION ALERT: Functional Gastrointestinal and Motility Disorders Research Enhancement Act of 2017 (HR 1187)
In early March 2017, the International Foundation for Functional Gastrointestinal Disorders (IFFGD) publicly made known that the Functional Gastrointestinal and Motility Disorders Research Enhancement Act of 2017, also known as HR 1187 was introduced in the United States House of Representatives on February 16, 2017. HR 1187 addresses public awareness efforts and research funding for …
U.S. Food and Drug Administration Issues Drug Safety Communication for IBS-D Medication Eluxadoline (Viberzi), March 2017
Today, March 15, 2017, IBS Impact learned via IFFGD social media that the U.S. Food and Drug Administration (FDA) issued a drug safety communication for eluxadoline (also known by the brand name Viberzi), currently used in treating irritable bowel syndrome with diarrhea in adults, 18 and older, both men and women. This warning applies specifically …
New Updates to IBS Impact.com Main Website for March 2017
IBS Impact has recently completed the latest round of updates to many pages of our main website, IBS Impact.com. A few links have been replaced with updated versions and several new ones have been added on the news footer, IBS page, advocacy page, research page, resources page, IBS and children page, family and friends page, …
IBS IMPACT 